Colon Targeted Pulsatile Drug Delivery : A Review

Sponsored Links

Rathod Shruti

Mrs. Rathod Shruti

Over the past two decades the major challenge for scientist is to target the drugs specifically to the colonic region of g.i.t. Previously colon was considered as a innocuous organ solely responsible for absorption of water, electrolytes & temporary storage of stools. But now it is accepted as important site for drug delivery. colon is used to treat –

  • Seriousness from constipation & diarrhoea to the debilitating inflammatory bowl diseases (ulcerative colitis & Crohn’s disease) through to colon carcinoma which is two third cause of cancer in both man & women.
  • Colon can be utilized as portal for the entry of drugs into the blood stream for the systemic therapy.
  • Colon having the lower level of luminal & mucosal digestive enzymes as compared with the small intestine reduces the chances of drug degradation.
  • Colon delivery also a mean of achieving chronotherapy of disease that are sensitive to circadian rhythm such as asthma & arthritis.

Targeted delivery ensures the direct treatment at the disease site, lower dosing, & reduction in side effects. 1, 2 

Approaches To Colonic Dru Delivery Through Oral Route

Oral route generally preferred by the patient than the rectal route. Colon is the most distal segment of g.i.t. that’s why orally administered drug must retard drug release in the upper g.i.t. but must release promptly on entry into the distal colonic part. In colon due to presence of low fluid volume & viscous nature of luminal content, the drug dissolution & release from the formulation may vary. Colonic microflora also shows impact on the stability of released drug. Inspite of these difficulties various approaches & systems have been developed to target the drug to the colon.

1. pH dependent delivery – In g.i.t. there is presence of pH gradient which approximately ranges from 1.2 in stomach, 6.6 in proximal small intestine, 7.5 in distal intestine & pH of colon is about 6.4. Generally Eudragit S is used for the colon delivery it dissolves at pH greater than 7.0, which results in premature drug release from the system. It is concluded that pH of g.i.t. was not a reliable criteria for colonic targeting. 3 Problem of premature drug release can be overcomed by the use of Eudragit FS. 4

2. Pressure dependent delivery – The pressure controlled colon delivery capsule utilizes the increase in pressure of the luminal contents of the colon. Increase in luminal pressure is due to reabsorption of water in this region. The drug is dispersed in suppository base & coated with ethyl cellulose for the preparation of such system. Temperature of body is responsible for suppository base to melt & increases the volume which forms balloon of ethyl cellulose filled with liquid. This balloon can withstand with the contraction of small intestine (peristalsis) but ruptures when subjected to intensive contraction in the colon & contents of thicker viscosity. This system is used for the production of single unit system. 5

3. Bacteria dependent delivery – In these system colonic bacteria are utilized to degrade the substrate. The bacterial amount has been estimated about 10 11 per gram in the colon & having around 400 species (anaerobic in nature). Earlier polymer cross linked with azo aeromatic groups was used but due to potential carcinogenic activity now a days natural polysaccharides are used. Natural polysaccharides generally undergo premature drug release so they are chemically modified or mixed with hydrophobic polymers. This polymer shows good film forming properties, resistant to pancreatic enzymes but they will undergo degradation due to bacterial enzyme. 6

4. Time dependent delivery (Pulsatile drug delivery) - Pulsatile release systems are formulated to undergo a lag-time of predetermined span of time of no release, followed by a rapid & complete release loaded drugs(s). The approach is based on the principle of delaying the time of drug release until the system transits from mouth to colon. A lag-time of 5 hours is usually considered sufficient since small intestine transit is about 3-4 hours, which is relatively constant and hardly affected by the nature of formulation administered. This system offers many advantages over conventional oral drug delivery systems like patient compliance, reduced dosage, reduced dosage frequency, avoidance of side effects, avoidance of peak & valley fluctuation, nearly constant drug level at the target site. 7

PULSATILE SYSTEM – A tool to increase therapeutic efficacy of drug

Image In recent years considerable attention has been focused on the development of pulsatile drug delivery system. Delivery system with pulsatile release pattern has gained most popular form of controlled drug delivery system because conventional systems with a continuous release are not ideal. Oral controlled drug delivery systems are generally used due to convenient dosage form & it also releases drug in constant or variable rates 8,9,10 . In these system drug release generally occurs within therapeutic window for prolong period of time. Hence these systems show sustained release of drug from dosage form.

Advantages of pulsatile drug delivery system

    1. Extended daytime or nighttime activity
    2. Reduced side effects
    3. Reduced dosage frequency
    4. Reduction in dose size
    5. Improved patient compliance
    6. Lower daily cost to patient due to fewer dosage units are required by the patient in therapy.
    7. Drug adapts to suit circadian rhythms of body functions or diseases.
    8. Drug targeting to specific site like colon.
    9. Protection of mucosa from irritating drugs.
    10. Drug loss is prevented by extensive first pass metabolism 11 .

The oral controlled drug delivery system with continuous release does not show suitability in various conditions of the body which require pulsatile release of drug defined as “a pulsatile release profile” & is characterized by a time period of no release (lag time) followed by a rapid & complete drug release of drug from dosage form. Conditions requiring pulsatile release includes – A number of hormones like rennin, aldosterone & cartisole which shows daily fluctuation in their blood levels. These changes are generally known as circadian rhythm which is responsible for changes in many functions of the body like activity of liver enzyme, blood pressure, intra-ocular pressure etc 12 . PH, gastric acid secretion in stomach, gastric emptying & gastric intestinal blood transfusion 13 . Various diseases are also dependent on the circadian rhythm for example acute myocardial insufficiency occurs most commonly around 4.00 P.M. & Epileptic seizures have the highest incidence in the morning, such conditions demands consideration of diurnal progress of disease rather than maintaining constant plasma drug level. In these conditions delivery system should be administered at night but it should release drug at morning time. Some other diseases are bronchial asthma, angina pectoris, rhumatic disease, ulcer & hypertension also required time dependent delivery 14 . Drugs responsible for producing biological tolerance also require pulsatile release. These systems prevent their continuous presence at the biophase. It releases drug after lag time (time at which drug is required by the body). For drugs required to be targeted in colonic region (distal organ) the delivery system should prevent release of drug in the upper two third portions in g.i.t 15, 16 . Drug with idiosyncratic pharmacokinetics or pharmacodynamics or drugs with extensive first pass metabolism or which show potential food interaction require pulsatile release of the drug. Some drugs induce nausea or vomiting or some cause gastric irritation or some undergo degradation in gastric acid medium, all such drug requires drug release after lag time. Pulsed fashion can be achieved by the enteric coating of delivery system 17 .

All above conditions are required chronotherapeutics (i.e. precisely time therapy). To accomplish the objectives & advantages of chronotherapeutics, time controlled pulsatile drug delivery devices are required they show releasing the right amount at the right time.

Ideal Pulsatile Drug Delivery System

The first pulsatile drug delivery formulation, which released active substance at a precisely defined time point was formulated in the early 1990s. The aim of the research was to obtain sigmoidal release pattern. Below drug release profile is for the single pulse release system 18, 19 .


Classification Of Pulsatile Or Time Controlled System

In this review attempt is made to review various time controlled drug delivery system based on rupturing of membrane or erosion of membrane. Time dependent dosage forms are formulated to release their drug load after a predetermined lag time. Alternative terms used are pulsatile release, delayed or sigmoidal release. Besides one-pulse systems, multiple systems release the drug in subsequent pulses. The application of pulsatile release systems can be advantageous to adapt a drug therapy to chronopharmacological needs or to target a drug specific site in the gastrointestinal tract, e.g. to the colon 20, 21, 22 . Lag time of 4-6 hours generally considered sufficient, since small intestine transit is about 3-4 hours, which is relatively constant. Formulation in which drug release is independent of the environmental factors like PH, enzymatic activity, intestinal motility, pressure etc. can be achieved by incorporating a lag-time into the formulation equivalent to mouth to colon transit time 23 . The pulsatile drug delivery systems are of two types –

  • Single unit system
  • Multiple (pellet system) unit system

Single Unit System

  1. Capsular system – Architecture of these systems generally consists of an insoluble capsule body housing, a drug & a plug. After a predetermined lag-time plug was removed because it undergoes swelling, erosion or dissolution. Example: pulsincap R system – In this system a water insoluble body containing the drug formulation, system is closed with a swell able hydrogel. Plugged (insoluble but permeable & swellable) at open end 24, 25 . Upon contact with, gastro-intestinal fluid or dissolution medium the plug swells pushing itself out of the capsule after lag-time. Position & dimensions of plug control lag-time. For rapid release of water insoluble drug effervescent or disintegrating agents are added. No gastrointestinal irritation can be observed in both human & animal 26, 27 . Plug material is generally made up of following –
    • Swellable materials coated with insoluble but permeable polymer (polymethacrylates)
    • Erodible compressed polymer (HPMC, polyvinyl alcohol, polyethylene oxide)
    • Congealed melted polymer (glyceryl monooleate)
    • Enzymatically controlled erodible polymer (pectin) 28, 29  

Disadvantages: These systems show variable gastric residence time & this problem is overcome by enteric coating 26 .

  1. Pulsatile delivery by osmosis – The Port R system consists of gelatin shell filled with osmotically active ingredient along with drug & also having an insoluble lipidic plug. Shell is coated with semi permeable membrane (cellulose acetate) then plugged with insoluble plug as well as system comes in contact with aqueous medium the water moves across semi-permeable membrane & exert pressure which remove the plug after lag-time 30 . System shows good in-vivo & in-vitro correlation in humans & used to deliver methylphenidate to schoolage children for the treatment of attention deficit hyper activity disorder (ADHD) 31, 32 .

Another system is also based on expendable orifice that contain capsular system in which liquid drug is absorbed on highly porous particles. Drug releases through orifice of a semipermeable capsule supported by an expending osmotic layer after the barrier layer is dissolved 33, 34, 35.

Still another system is based on delivery by a series of stop. In this system the capsule contains a drug & water absorptive water engine that are placed in compartment separated by a movable partition. These stops obstruct the movement of partition but are overcome in succession when osmotic pressure rises above threshold level 36 .

  1. Pulsatile delivery by erosion or solublization of coating – Most of the pulsatile drug delivery systems are reservoir devices coated with a barrier layer. This barrier erodes or dissolves after specified lag period & drug is subsequently released rapidly. The lag time depends on the thickness of the coating layer 37, 38, 39 . Example: The Time Clock system consists of solid dosage form coated with lipid barriers such as carnauba wax & beeswax along with surfactants like polyoxyethylene sorbitan monooleate 40, 41 . When this system comes in contact with the aqueous medium the coat emulsifies or erodes after the lag-time depending on the thickness of coat. The lag time of system is independent of the gastrointestinal motility, PH, enzyme & gastric residence time 42 .

Advantage: Ease of manufacturing.

Disadvantages: In-vivo variability (food effects which is present in G.I.T.).

In another example the Chronotropic R system consists of solid dosage form coated with hydrophilic swellable hydroxy propyl methyl cellulose which releases drug after lag-time depending on thickness of coat & viscosity grade of hydroxypropyl methyl cellulose. The system is suitable for both tablet & capsule        dosage form, both in-vivo & in-vitro lag times shows good correlation with the applied amount of the hydrophilic retarding polymer 43, 44, 45 .Multi layered tablet – with the three layered tablet release pattern with two pulses was obtained,  two drug layers are separated by a drug free gellable polymeric barrier layer (like HPMC, methacrylic & acrylic polymers or polyalcohols) 46, 47 .

4. Pulsatile delivery by rupture of membrane – The other class of the reservoir type pulsatile system is  based on rupturable coatings. The drug release from the core occurs when sorrounding polymeric  membrane undergo ruptured due to inbuilt pressure within system. The effervescent excipients produces gas or osmotic agent produces osmotic pressure or swelling agent cause swelling, one of   these is necessary for rupture of coating 48, 49, 50, 51 . Citric acid & sodium bicarbonate is incorporated as   effervescent mixture in tablet core coated with ethyl cellulose, when system comes in contact with water it produces carbon dioxide gas which exerts pressure & after lag time rupture the membrane & rapid release of drug occurs. A reservoir system with a semi permeable coating is proposed especially with drugs with high first pass effect in order to obtain in-vivo drug pattern similar to the administration of several immediate release doses croscarmellose sodium starch glycollate or low substituted hydroxy propyl cellulose were used as swelling substances, which resulted in complete film rupture followed by rapid drug release. The lag time is controlled by composition of outer polymeric membrane (HPMC water soluble polymer increased permeability decreased lag-time) 52,                          53 .

Multiparticulate System

Multiparticulate systems are reservoir type of devices with a coating, which either ruptures or changes its permeability. Drug is coated over sugar seeds these granules may then be packaged in a capsule or compressed with additional excipients to form a tablet. The active pharmaceutical ingredient may also be blended or granulated with polymers before coating to provide an additional level of control. However, drug loading in this type of system is low due to higher need of excipients 54,  55.

 These systems show various advantages over single unit systems, which includes –

  • Short gastric residence time
  • Reproducible gastric residence time
  • No risk of dose dumping
  • Flexible to blend pellets with different composition or release pattern
  • Lowest transit time variability
  • Unique profiles
  • Amenable to capsule & tablets
  • Capable of pulsatile release
Disadvantages –
  • Multiple manufacturing steps
  • Low drug load
  • Incomplete release
  1. Pulsatile release by rupturing of membrane – In these multiparticulate system drug is coated on sugar seeds & then coated with insoluble & swellable top layer 56, 57, 58 . The swelling agent includes superdisintegrents like carboxy methylcellulose, sodium starch glycollate, L-hydroxy propyl cellulose. Polymers like polyacrylic acid, polyethylene glycol etc. alternatively comprising of a mixture of tartaric acid & sodium bicarbonate that used as effervescent agent. Water ingress to system causes the coating to swell, rupture & release of drug occurs. Release of drug is independent of pH or solubility of drug. Lag-time can be varied by varying thickness of coating or by changing amount of plasticizers in the outermost layer. If concentration of osmotic agent increases rapid release of drug after lag-time can be observed. In-vivo studies of time controlled explosion system with an in-vitro lag-time of three hours showed appearance of drug in blood after 3 hours, and maximum level after 5 hours 59, 60, 61 .
  1. Rupturable coating with osmosis – These system contains core having drug (low bulk density solid or liquid lipid material) & disintegrant. Core is coated with cellulose acetate polymer. System is combination of swelling & osmotic effect, upon immersion in aqueous medium, water penetrates the core, displaces the lipid material, after depletion of lipid material internal pressure increases until a critical stress is reached, which causes rupture of coating 62, .

Another type of system is one in which tablet or capsule is composed of large number of pellets (two or more pellets) 63 . Single pellet of this system contains drug plus osmotic agent & coated with water permeable, water insoluble polymer. In film hydrophobic agent (water insoluble) is incorporated which alters permeability. The rate of water influx & drug efflux causes the film coating of each population to differ from any other pellet coating in the dosage form. Pellet gets swelled due to dissolution of osmotic agent as it comes in contact with water resulting in regulation of diffusion & release of drug content from pellet. Each pellet population of system shows this effect. The coating thickness may vary & this system is used for antihypertensive drug diltiazem. Osmotically active compound don’t undergo swelling, the use of osmotic active agent was reported by Shultz & Kleinbudde 62, 63 . The pellet core made up of drug, sodium chloride & coated with semipermeable cellulose acetate polymer (permeable to water & not to drug). Varying thickness of coating & amount of plasticizer in coating can vary lag-time of system. Sodium chloride provides fast release of drug if it is absent in core then a sustained release was observed after lag-time due to lower degree of swelling & generation of small fissures in core. Chen 63, 64 has also reported a system-containing core of drug & osmotically active agent coated with insoluble permeable membrane.

3.   Change in membrane permeability based pulsatile release – The permeability & water uptake of acrylic polymers with quaternary ammonium groups can be influenced by the presence of different counter ions 65 . Several delivery system with sigmoidal or pulsatile release based on these ion exchange have been developed Eudragit RS 30D is polymer of choice, it contains positively polarized quaternary ammonium group in the polymer side chain & also negative hydro chloride counter ions. The ammonium group is hydrophilic causes interaction with water & changes in permeability of it in controlled manner. In these system core containing drug & sodium acetate coated with four different layer of Eudragit RS30D. Small amount of sodium acetate dramatically change the permeability of eudragit film. After lagtime permeability increases due to increase in interaction between eudragit & acetate, resulting in entire drug release within few minutes. Increase in lag-time occurs as thickness increases but it has no effect on release 66 .

Sigmoidal release system consists of drug & succinic acid core coated with ammonio-methacrylate copolymer USP/NF TYPE B. The lag-time is controlled by the rate of water influx through polymer membrane. Succinic acid dissolves by the water causes increase in permeability of hydrated polymer film that increases free volume. These findings were used to design acid containing core that is coated by polymeric membrane 67, 68, 69, 70 .


Successful colonic delivery can be obtained by pulsatile system for drugs with a high first pass effect, requiring dosing hora somni, site specific absorption & showing chronopharmacological behaviour. A number of formulations with single & multiple unit systems have been designed in recent past but most lack the site specificity. Therefore, there is a need to comprehend the effect of the biological environment on release performance so that a successful design with expected in vivo performance can be developed.


  1. Valentine CI, Richard AK & Abdul WB. Drug delivery to colon. The drug delivery componies report summer 2004.
  2. Basit AW, Lacey LF. Int J Pharm 2001, 227: 157-165.
  3. Ashford M, Fell JT, Attwood D, Sharma H, Woodhead PJ. Int J Pharm 1993a, 95: 193-199.
  4. Evans DF, Pye G, Bramley R, Hardcastle JD. Gut 1988, 29:1035-1041
  5. Takaya T, Ikada C, Imagawa N, Niwa K, Takada K. J Pharm Pharmacol 1995, 47:474-478.
  6. Saffron M, Kumar GS, Sabvariar C, Burnham JC, Williams F, Neckers DC. Science 1986, 233: 1081-1084.
  7. Wilding IR, Davis SS, Bakhshaee M, Stevens HNE, Sparrow RA, Brennan J. Pharm Res 1992, 9: 654-657.
  8. Gennaro AR , ed. Remington: The Science and Practice of Pharmacy. 20th ed. USA : Lippincott, Williams & Wilkins; 2000, 20:903-905.
  9. Bussemer T, Otto I, Bodmeier R. Pulsatile drug delivery systems. Crit Rev Ther Drug Carrier Syst. 2001;18(5):433-58.
  10. Review. Das NG, Das SK. Controlled release of oral dosage forms, formulation, finish, and fill. 2003;10-16.
  11. Umang Pharmatech Pvt. Ltd., Umang offers Road to Pelletisation through spher’odization. Express Pharma Pulse, 2000.
  12. Gurny R, Junginger HE, Peppas N. Pulsatile Drug Delivery: Current Applications and Future Trends. Stuttgart , Germany : Wissenschaftliche Verlagsgesellschaft;1993.
  13. Goo RH, Moore JG, Greenberg E, Alazraki NP. Circadian variation in gastric emptying of meals in humans. Gastroenterol. 1987;93(3):515-518.
  14. Lemmer B. Chronopharmacokinetics: implications for drug treatment. J Pharm Pharmacol. 1999;51:887-890.
  15. Dethlefsen U, Repges R. Ein neues therapieprinzip bei nächtlichem asthma. Med Klinik. 1985;80:44-47.
  16. Chourasia MK, Jain SK. Pharmaceutical approaches to colon targeted drug delivery systems. J Pharm Pharmaceut Sci. 2003;6(1):33-66.
  17. Lachman L, Lieberman HA, Kanig JL, The Theory and Practice of Industrial Pharmacy. Vol. 3. India : Verghese Publishing House; 1991.
  18. Chang R-K, Guo X, Burside BA, Couch RA, Rudnic EM. Formulation approaches for oral pulsatile drug delivery. Amer Pharma Rev. 1999;2(1):51-57.
  19. Petereit HU. Pulsed release drug delivery. 2003:101-104.
  20. Vinay kumar et al. Basic physiology. 5 th editon, W>B> saundres componey, 1992, 21.
  21. Chang R.K. et al. American pharmaceutical review, 1999,21.
  22. Lammer B. J Pharmacol. 51, 1999, 887.
  23. Wilding IR, Davis SS, Bakhshaee M et al. Pharm Res, 9:654-657, 1992.
  24. McNeil ME, Rashid A, Stevens HNE. Dispensing Device. WO Patent No. 90/09168 (1990).
  25. Wilding IR, Davis SS, Bakhshaee M, Stevens HNE, Sparrow RA, Brennan J. Gastrointestinal transit and systemic absorption of captopril from a pulsed-release formulation. Pharm Res.1992;9:654-657.
  26. Saeger H, Virley P. Pulsincap& Mac226: Pulsed-Release Dosage Form. Product information from Scherer DDS, Ltd; 2004.
  27. Binns J, Stevens HNE, McEwen J, Pritchard G, Brewer FM, Clarke A, Johnson ES, McMillan I. The tolerability of multiple oral doses of Pulsincap & Mac226 capsules in healthy volunteers. J Control Rel. 1996;38:151-158.
  28. Krögel I, Bodmeier R. Pulsatile drug release from an insoluble capsule body controlled by an erodible plug. Pharm Res. 1998;15(3):474-481.
  29. Krögel I, Bodmeier R. Evaluation of an enzyme-containing capsular shaped pulsatile drug delivery system. Pharm Res. 1999;16(9):1424-1429.
  30. Crison JR, Siersma PR, Taylor MD, Amidon GL. Programmable oral release technology, Port Systems & Mac226: a novel dosage form for time and site specific oral drug delivery. Proceed Intern Symp Control Rel Bioact Mater. 1995;22:278-279.
  31. Crison JR, Siersma PR, Amidon GL. A novel programmable oral release technology for delivering drugs: human feasibility testing using gamma scintigraphy. Proceed Intern Symp Control Rel Bioact Mater. 1996;23:51-52.
  32. Crison JR, Vieira ML, Kim J-S, Siersma C, Amidon GL. Pulse delivery of methylphenidate in dogs using an osmotic drug delivery system. Proceed Intern Symp Control Rel Bioact Mater. 2001;28:6101.
  33. Pollock-Dove C, Dong L, Wong P. A new system to deliver a delayed bolus of liquid drug formulation. Proceed Intern Symp Control Rel Bioact Mater. 2001;28:6033.
  34. Linkwitz A, Magruder JA, Merrill S. Osmotically Driven Delivery Device with Expandable Orifice for Pulsatile Delivery Effect. US Patent No. 5,318,558; 1994.
  35. Linkwitz A, Magruder JA, Merrill S. Osmotically Driven Delivery Device with Expandable Orifice for Pulsatile Delivery Effect. US Patent No. 5,221,278; 1993.
  36. Balaban SM, Pike JB, Smith JP, Baile CA. Osmotically Driven Delivery Devices with Pulsatile Effect. US Patent No. 5209746; 1993.
  37. Magruder PR, Barclay B, Wong PSL, Theeuwes F. Composition Comprising Salbutamol. US Patent No. 4751071; 1988.
  38. Magruder PR, Barclay B, Wong PSL, Theeuwes F. Constant Release System with Pulsed Release. US Patent No. 4777049; 1988.
  39. Magruder PR, Barclay B, Wong PSL, Theeuwes F. Composition Comprising a Therapeutic Agent and a Modulating Agent. US Patent No. 4851229; 1989.
  40. Pozzi F, Furlani P. Orale Feste Pharmazeutische Darreichungsform Mit Programmierter Freisetzung. DE Patent No. 4122039; 1992.
  41. Wilding IR, Davis SS, Pozzi F, Furlani P, Gazzaniga A. Enteric coated timed release systems for colonic targeting. Int J Pharm. 1994;111:99-102.
  42. Niwa K, Takaya T, Morimoto T, Takada I. Preparation and evaluation of a time controlled release capsule made of ethyl cellulose for colon delivery of drugs. J Drug Target. 1995;3:83-89.
  43. Gazzaniga A, Iamartino P, Maffione G, Sangalli ME. Oral delayed-release system for colonic specific delivery. Int J Pharm. 1994;2(108):77-83.
  44. Gazzaniga A, Sangalli ME, Giordano F. Oral chronotopic & Mac226: drug delivery systems: achievement of time and/or site specifity. Eur J Biopharm. 1994;40(4):246-250.
  45. Gazzaniga A, Busetti C, Moro L, Crimella T, Sangalli ME, Giordano F. Evaluation of low viscosity HPMC as retarding coating material in the preparation of a time-based oral colon specific delivery system. Proceed Intern Symp Control Rel Bioact Mater. 1995;22:242-243.
  46. Poli S, Busetti C, Moro L. Oral Pharmaceutical Composition for Specific Colon Delivery. EP Patent No. 0,572,942; 1993.
  47. Sangalli ME, Maroni A, Zema L, Busetti C, Giordano F, Gazzaniga A. In vitro and in vivo evaluation of an oral system for time and/or site-specific drug delivery. J Contr Rel. 2001;73:103-110.
  48. Maroni A, Sangalli ME, Cerea M, Busetti C, Giordano F, Gazzaniga A. Low viscosity HPMC coating of soft and hard gelatin capsules for delayed and colonic release: preliminary investigations on process parameters and in vitro release performances. Proceed Int Control Rel Bioact Mater. 1999;26:887-888.
  49. Conte U, Colombo P, La Manna A, Gazzaniga A. A new ibuprofen pulsed release oral dosage Dev Ind Pharm. 1989;15(14-16):2583-2596.
  50. Conte U, La Manna A, Colombo P. Tablet for Pharmaceutical Use Able to Release Active Substances At Successive Times. US Patent No. 4,865,849; 1989.
  51. Conte U, Giunchedi P, Maggi L, Sangalli ME, Gazzaniga A, Colombo P, La Manna A. Ibuprofen delayed release dosage forms: a proposal for the preparation of an in vitro/in vivo pulsatile system. Eur J Pharm. 1992;38(6):209-212.
  52. Krögel I, Bodmeier R. Floating or pulsatile drug delivery systems based on coated effervescent cores. Int J Pharm. 1999;187:175-184.
  53. Amidon GL, Leesman GD. Pulsatile Drug Delivery System. US Patent No. 5,229,131; 1993.
  54. Daumesnil R. Marketing Considerations for multiparticulate drug delivery systems. In: Ghebre-Sellassie I, ed. Multiparticulate Oral Drug Delivery. New York , NY : Marcel Dekker, Inc.; 1994:457-474.
  55. Ueda Y, Hata T, Yamaguchi H, Ueda S, Kotani M. Time Controlled Explosion System and Process for Preparation for the Same. US Patent No. 4,871,549;1989.
  56. Ueda Y, Hata T, Yamaguchi H, Kotani M, Ueda S. Development of a novel drug release system, time-controlled explosion system (TES). Part 1: concept and design. J Drug Targeting. 1994;2:35-44.
  57. Ueda S, Yamaguchi H, Kotani M, Kimura S, Tokunaga Y, Kagayama A, Hata T. Development of a novel drug release system, time-controlled explosion system (TES). Part II: design of multiparticulate TES and in vitro drug release properties. Chem Pharm Bull. 1994;42(2):359-363.
  58. Ueda S, Ibuki R, Kimura S, Murata S, Takahashi T, Tokunaga Y, Hata T. Development of a novel drug release system, time controlled explosion system (TES). Part III: relation between lag time and membrane thickness. Chem Pharm Bull. 1994;42(2):364-367.
  59. Hata T, Shimazaki Y, Kagayama A, Tamura S, Ueda S. Development of a novel drug delivery system (TES): Part V: animal pharmacodynamic study and human bioavailability study. Int J Pharm. 1994;110:1-7.
  60. Chen C-M. Multiparticulate Pulsatile Drug Delivery System. US Patent No. 5,508,040; 1996.
  61. Schultz P, Kleinebudde P. A new multiparticulate delayed release system. Part I: dissolution properties and release mechanism. J Contr Rel. 1997;47:181-189.
  62. Schultz P, Tho I, Kleinebudde P. A new multiparticulate delayed release system. Part II: coating formulation and properties of free films. J Contr Rel. 1997; 47:191-199.
  63. Chen C-M. Pulsatile Particles Drug Delivery System. US Patent No. 5,260,068; 1993.
  64. Bodmeier R, Guo X, Sarabia RE, Skultety P. The influence of buffer species and strength on diltiazem HCl release from beads coated with aqueous cationic polymer dispersions, Eudragit RS, RL 30D. Pharm Res. 1996;13(1):52-56.
  65. Beckert TE, Pogarell K, Hack I, Petereit H-U. Pulsed drug release with film coatings of Eudragit & Mac226; RS 30D. Proceed Int’l Symp Control Rel Bioact Mater. 1999;26:533-534.
  66. Guo X. Physicochemical and Mechanical Properties Influencing the Drug Release From Coated Dosage Forms. Doctoral Thesis. The University of Texas at Austin ;1996.
  67. Narisawa S, Nagata M, Danyoshi C, Yoshino H, Murata K, Hirakawa Y, Noda K. An organic acid-induced sigmoidal release system for oral controlled-release preparations. Pharm Res. 1994;11(1):111-116.
  68. Narisawa S, Nagata M, Hirakawa Y, Kobayashi M, Yoshino H. An organic acid-induced sigmoidal release system for oral controlled-release preparations. Part II: permeability enhancement of Eudragit RS coating led by the physicochemical interactions with organic acid. J Pharm Sci. 1996;85(2):184-188.
  69. Narisawa S, Nagata M, Ito T, Yoshino H, Hirakawa Y, Noda K. Drug release behavior in gastrointestinal tract of beagle dogs from multiple unit type rate-controlled or time-controlled release preparations coated with insoluble polymer-based film. J Contr Rel. 1995;33:253-260.

About Authors:

Dr. Ram Alpana

Dr. Ram Alpana

Head of department , SLTI of Pharmaceutical Sciences,  G. G. D. U. Bilaspur (C.G.),INDIA
Phone Number – 07752/254350, 94252/23746

Rathod Shruti

Mrs. Rathod Shruti

Principal, SiddiVinayaka Institute of Technology & Sciences(Collage of Pharmacy) , Near to balram Talkies, Nehru Nagar, Bilaspur (C.G.), INDIA

Volumes and Issues: 


Thiruganesh's picture

MR. Thiruganesh

MR. Thiruganesh

MVRR's picture

Shruti madam Yours presentation is very nice, and it is beneficial for novel investigation.Iam intrested to do a project on pulsatile drug delivery by colon targetting or colon targeted pulsatile drug delivery.., Can u suggest me how to approach for this project and in what way we can prepare this type of tablets.

Similar Entries

  • Development of more “User-Friendly” dosage form ultimately increases dosing convenience for the patient. Living organisms require different amounts of drug at predictably different times within the circadian cycle which will maximize therapeutic and minimize undesired drug effects. Concept of chronopharmaceutics wherein, research is devoted to the design and evaluation of drug delivery systems that release a therapeutic agent at a rhythm that ideally matches the biological requirement of a given disease therapy. Diseases where a constant drug levels are not preferred, but needs a pulse of therapeutic concentration in a periodic manner and diseases with established oscillatory rhythm in their pathogenesis includes asthma, arthritis, duodenal ulcer, cancer, cardiovascular diseases (example hypertension and acute myocardial infarction), hypercholesterolemia, and ulcer acts as a push for the development of “Pulsatile Drug Delivery Systems “. In these systems, there is rapid and transient release of a certain amount of drug molecules within a short time-period immediately after a predetermined off release period. Various techniques are available for the pulsatile delivery like pH dependent systems, time dependent systems, micro-flora activated systems, etc. which can be designed as per the physiology of disease and properties of the drug molecule. Pulsatile drug delivery system is time and site specific drug delivery system, thus providing special and temporal delivery and increasing patient compliance. Pulsatile drug delivery system is defined as the rapid and transient release of certain amount of molecules within a short time period immediately after predetermined off-release periods i.e. lag time. Advantages of the pulsatile drug delivery system are reduced dose frequency; reduce side effects, drug targetting to specefic site like colon, protection of mucosa from irritating drug and many more. Now in market varies technologies of pulsatile drug delivery system like OROS, CODAS and etc. are launched by some pharmacuetical companies.

  • Historically, extended release dosage forms were developed, which release the drug continuously over longer periods of time. Recently, however, delivery systems with a pulsatile-release pattern are receiving increasing interest for the development of drugs for which conventional continuous release systems are not ideal. A pulsatile-release profile is characterized by a time period of no release (lag time) followed by a rapid and complete drug release.

    Pulsatile drug-delivery systems can be classified into site-specific systems or time-controlled devices. These systems are designed according to the circadian rhythm of the body. The principle rationale for the use of pulsatile release is for the drugs where a constant drug release, i.e., a zero-order release is not desired. These systems are beneficial for the drugs having chronopharmacological behaviour where night time dosing is required and for the drugs having high first-pass effect and having specific site of absorption in GIT. Drugs used in asthmatic patients and patients suffering from rheumatoid arthritis are also discussed along with many other examples.

    This review covers diverse aspects like introduction to chronopharmaceutics, principle, formulation, technologies employed, pharmacokinetics, pharmocadynamics, new global trends, to name a few.

  • Pulsatile drug delivery system (PDDS) are gaining importance as these systems deliver the drug at the right site action at right time and in right

  • Colonic drug delivery has gained increased importance not just for the delivery of the drugs for the treatment of local diseases associated with the colon but also for its potential for the delivery of proteins and therapeutic peptides. To achieve successful colonic delivery, a drug needs to be protected from absorption and /or the environment of the upper gastrointestinal tarct and then by abruptly release into the proximal colon, which is considered the optimum site for the colon- targeted delivery of drugs.

    Colon targeting naturally of value for the topical treatment of diseases of colon such as Chron’s diseases, ulcerative colitis, colorectal cancer and amebiasis. Peptides, proteins, oligonucleotides and vaccines pose potential candidature for colon targeted drug delivery.

    The various strategies for targeting orally administered drugs to the colon include covalent linkage of a drug with a carrier, coating with pH-sensitive polymers, formulation of time released systems, exploitation of carriers that are degraded specifically by colonic bacteria, bioadhesive systems and osmotic controlled drug delivery system. Microbial degradable polymers especially azo crosslink polymers have been investigated for use in targeting of drugs to colon. Certain plant polysaccharides such as amylose, insulin, pectin and guar gum remains unaffected in the presence of gastrointestinal enzymes and have the way for the formulations of colon targeted drug delivery systems. The concept of using pH as a rigger to release drug in the colon is based on the pH condition that vary continuously down gastrointestinal tract. Times dependent drug delivery systems have been developed that are based on the principle to prevent release of drug until 3-4 hr after living the stomach. Redox sensitive polymers and bioadhesive systems have also been exploited to deliver the drugs into the colon.

  • The expanding arena of emerging drugs, increased sensitivity to clinical outcomes and healthcare costs are driving the need for alternative drug

  • Anju Gauniya

    Anju Gauniya